Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Seneca Growth Capital Vct Plc LSE:HYG London Ordinary Share GB0031256109 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 33.50 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
27.00 40.00 33.50 33.50 33.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments -0.16 3
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 33.50 GBX

Seneca Growth Capital Vct (HYG) Latest News

Seneca Growth Capital Vct News

Date Time Source Headline
24/6/202012:35UKREGSeneca Growth Capital VCT plc B Share - Extension Of Offer
More Seneca Growth Capital Vct News
Seneca Growth Capital Vct Investors    Seneca Growth Capital Vct Takeover Rumours

Seneca Growth Capital Vct (HYG) Discussions and Chat

Seneca Growth Capital Vct Forums and Chat

Date Time Title Posts
07/4/202116:38HYGEA VCT : medical technology company VCT239
17/1/200519:21Honeygrove Group - was Propan Homes514
23/10/200321:33PETER O'REILLY UPS STAKE, SOMETHING GOING On4
16/10/200316:41HYG Charts2

Add a New Thread

Seneca Growth Capital Vct (HYG) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Seneca Growth Capital Vct trades in real-time

Seneca Growth Capital Vct (HYG) Top Chat Posts

DateSubject
17/4/2021
09:20
Seneca Growth Capital Vct Daily Update: Seneca Growth Capital Vct Plc is listed in the Equity Investment Instruments sector of the London Stock Exchange with ticker HYG. The last closing price for Seneca Growth Capital Vct was 33.50p.
Seneca Growth Capital Vct Plc has a 4 week average price of 33.50p and a 12 week average price of 22p.
The 1 year high share price is 37.70p while the 1 year low share price is currently 17.50p.
There are currently 8,115,376 shares in issue and the average daily traded volume is 1,595 shares. The market capitalisation of Seneca Growth Capital Vct Plc is £2,718,650.96.
07/4/2021
16:38
jonesy100: Thanks Rivaldo. I still think SCLP may be taken private before full value is realised. The heavy HYG div payouts over last few years have definitely taken out some of the downside risk from my perspective so will hold to the end like you.
15/2/2021
11:36
jonesy100: Yep. HYG Nav is 38p [edit] with Scancell at 20p. I think Scancell is 70 percent of NAV with cash and unquoted making up the rest
15/2/2021
11:05
rivaldo: Agreed :o)) SCLP has now settled down at 20p, so that's worth ££2.4m to HYG. Unless they sold some at this morning's top of 27p or so.....
15/2/2021
08:36
rivaldo: SCLP up to 22p :o)) HYG have 12m shares.....
16/9/2020
07:28
rivaldo: Confirmation that the NAV is now 35.8p per share: Https://www.londonstockexchange.com/news-article/HYG/investment-realisations-and-nav/14687131 They've sold all the ODX shares, and also 1.05m SCLP shares - so the remainder are exactly 12m SCLP shares. IMO they may regret this - both ODX and SCLP have already gone up since they sold.
15/9/2020
15:13
jonesy100: Yes and I see the HYG price has started to move now in the feed although no trades. 33/25 is closer to what I would expect given historic discount. Am very happy other than they sold off so much ODX early in the run.
13/8/2020
09:16
rivaldo: Today's fall is due to the 8p divi - though the price has actually been marked down 10p. And someone sold 5k at just 14p! I wonder if they were unnecessarily panicked by the fall. I calculate that leaves around £500k cash, plus 400k ODX shares, 13.05m SCLP shares, plus essentially £200k each in Arecor and Fuel 3D and £120k in Insense Ltd. There are 8.115m shares in issue.
30/7/2020
19:40
jonesy100: Just digesting this. Nice divi but share your frustration with ODX. Not sure why they took profits so low. My calculation is that at today's share price the new NAV is 33.8p so 25.8p ex div. Given usual discount, new baseline is 20p
30/7/2020
08:26
rivaldo: H1 results are out - NAV was 30.2p at 30th June. But we get an 8p interim divi - wahey! Thanks to the ODX share sales, which have left HYG with £1.16m of net cash. Since 30th June, the 400,000 ODX shares have increased from 41p to today's 64p, whilst the 13.05m SCLP shares have increased from 5.2p to today's 6.75p. OR Productivity has been a disaster and is now completely written off. Glad I wasn't drawn in to investing in this separately. I note there's no explanation as to what happened. HYG is essentially now almost a complete bet on SCLP, with solid backing from ODX and Arecor. I wish they'd retained more ODX shares, as there could be lots more upside: Https://www.londonstockexchange.com/news-article/HYG/half-year-report/14634116
04/5/2020
10:26
rivaldo: Nice to see someone pick up on the holdings in ODX and SCLP: Https://www.theaic.co.uk/aic/news/citywire-news/seneca-vct-leaps-on-omega%E2%80%99s-covid-19-success "Seneca VCT leaps on Omega’s Covid-19 success 1 May 2020 Seneca Growth Capital VCT, a small venture capital trust, has bucked the turmoil in global markets thanks to a holding in Omega Diagnostics, a company developing an antibody test for Covid-19. Seneca Growth Capital VCT (HYG ), a small venture capital trust, has bucked the turmoil in global markets thanks to a holding in a company developing an antibody test for Covid-19. Shares in Omega Diagnostics (ODX) soared after it won regulatory approval to manufacture its antibody, which can reveal whether someone previously exposed to the virus has built up some immunity to it. It has the potential to produce up to 46,000 tests a day. Having started April at 7.63p they closed at 60.5p on Monday and have traded at around 55p since. The AIM-quoted company has entered into an agreement to produce the laboratory test, developed by Mologic, which last week received independent validation by the Liverpool School of Tropical Medicine and St George’s, University of London. Ongoing validations are being performed by Public Health England, NHS Scotland and the Republic of Ireland, but Omega announced the test is now CE-marked, confirming it adheres to EU safety guidelines. Seneca announced on Monday evening that after selling more shares on the latest rise, the Growth Capital VCT’s pool of ordinary shares had booked a £328,000 profit from the sale of 1.7m Omega shares, adding 18.1% to its net asset value (NAV) in just a week to leave it with 35.8p NAV per ordinary share. It retains 600,000 shares in Omega, one of two quoted stocks in the largely unquoted portfolio, whose position in the VCT was valued at £321,000 at the end of last year. Since 18 February when the pandemic broke and markets fell, the VCT shares jumped 41% from 22p to 31p, though they have settled back today, down 1.5p or 4.9% at 29.5p. This is a turnaround for the VCT whose performance last year was weighed down by a large investment in Scancell, an AIM-listed biotechnology company developing vaccines to target various types of cancer. Separately, on 9 April Omega partnered with three other companies and Oxford University to jointly develop and manufacture a Covid-19 antibody test, in order to determine whether people have developed immunity after contracting the virus, which can be used at home. This will be manufactured at Omega’s facility in Alva, Scotland. The news has been another factor in Omega’s rising share price this month, to levels closer to when it listed on AIM in 2006."
Seneca Growth Capital Vct share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
HYG
Seneca Gro..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210417 09:52:42